A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2)
Year: 2009
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: J. Shih, C. Yang, W. Su, T. Hsia, C. Tsai, Y. Chen, H. Chang, E. Terlizzi, M. Shahidi, V. A. Miller
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2520471025